Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 ...

TORONTO, May 13, 2025 /CNW/ - Lilly Canada is pleased to announce that Mounjaro ® KwikPen ® (tirzepatide injection) is now available in Canada in all doses, offering a convenient treatment ...

Cost and availability: Tirzepatide is newer to the market and may be less widely available or more expensive than semaglutide.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight ...

Life science operators in the Greater Boston area just can't catch a break and things aren't expected to get better any time soon. The market generated a total availability rate of 26.9 percent in ...

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...

Eli Lilly is now offering cheaper single-dose vials of its wildly popular weight-loss drug Zepbound (tirzepatide), previously listed at $1,059 at month.

Federal regulators shook up the weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer in shortage after nearly two years, drawing the ire of compounding pharmacies.

Eli Lilly Weight Loss Drug in India: Eli Lilly has launched Mounjaro in India, a groundbreaking weight loss and diabetes drug, at a fraction of its US price. The once-weekly injectable improves ...

TheEgypt Buy Now Pay Later Business and Investment Report 2025: A $4.74 Billion Market by 2030 - Shahry and ValU are Leading, Innovating to Address Gaps in Credit Availability and Meeting Consumer ...